Detection of BRAF V600E mutations in papillary thyroid carcinomas by peptide nucleic acid clamp real-time PCR: A comparison with direct sequencing

Korean Journal of Pathology

Volumn 46, Issue 1, 2012, Pages 61-67

  Jeong, Dongjun ^a   Jeong, Yujun ^a   Lee, Sungche ^a   Lee, Hyeran ^a   Lee, Wanju ^b   Kim, Hyungjoo ^a   Park, Doosan ^a   Park, Soyoung ^a   Mu, Wenxia ^a   Cho, Hyun Deuk ^a   Oh, Mee Hye ^a   Lee, Sung Soo ^a   Yang, Seung Ha ^a   Kim, Chang Jin ^a  

^a Soonchunhyang University College of Medicine   (South Korea)

^b Soonchunhyang University   (South Korea)

Author keywords

BRAF; Peptide nucleic acids; Thyroid; Thyroid cancer papillary

Indexed keywords

EID: 84863231928     PISSN: 17381843     EISSN: None     Source Type: Journal    
DOI: 10.4132/KoreanJPathol.2012.46.1.61     Document Type: Article

References (30)

1. Segev DL, Umbricht C, Zeiger MA. Molecular pathogenesis of thyroid cancer. Surg Oncol 2003; 12: 69-90.
2. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 1993; 114: 1050-7.
3. Cohen Y, Xing M, Mambo E, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 2003; 95: 625-7.
4. Fukushima T, Suzuki S, Mashiko M, et al. BRAF mutations in papillary carcinomas of the thyroid. Oncogene 2003; 22: 6455-7.
5. Bonner TI, Kerby SB, Sutrave P, Gunnell MA, Mark G, Rapp UR. Structure and biological activity of human homologs of the raf/mil oncogene. Mol Cell Biol 1985; 5: 1400-7.
6. Huleihel M, Goldsborough M, Cleveland J, Gunnell M, Bonner T, Rapp UR. Characterization of murine A-raf, a new oncogene related to the v-raf oncogene. Mol Cell Biol 1986; 6: 2655-62.
7. Beck TW, Huleihel M, Gunnell M, Bonner TI, Rapp UR. The complete coding sequence of the human A-raf-1 oncogene and transforming activity of a human A-raf carrying retrovirus. Nucleic Acids Res 1987; 15: 595-609.
8. Ikawa S, Fukui M, Ueyama Y, Tamaoki N, Yamamoto T, Toyoshima K. B-raf, a new member of the raf family, is activated by DNA rearrangement. Mol Cell Biol 1988; 8: 2651-4.
9. Kumar R, Angelini S, Czene K, et al. BRAF mutations in metastatic melanoma: a possible association with clinical outcome. Clin Cancer Res 2003; 9: 3362-8.
10. Xing M, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005; 90: 6373-9.
11. Fugazzola L, Mannavola D, Cirello V, et al. BRAF mutations in an Italian cohort of thyroid cancers. Clin Endocrinol (Oxf) 2004; 61: 239-43.
12. Kim KH, Kang DW, Kim SH, Seong IO, Kang DY. Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J 2004; 45: 818-21.
13. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003; 63: 1454-7.
14. Rowe LR, Bentz BG, Bentz JS. Detection of BRAF V600E activating mutation in papillary thyroid carcinoma using PCR with allele-specific fluorescent probe melting curve analysis. J Clin Pathol 2007; 60: 1211-5.
15. Sapio MR, Posca D, Troncone G, et al. Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA). Eur J Endocrinol 2006; 154: 341-8.
16. Hayashida N, Namba H, Kumagai A, et al. A rapid and simple detection method for the BRAF(T1796A) mutation in fine-needle aspirated thyroid carcinoma cells. Thyroid 2004; 14: 910-5.
17. Kim SK, Song KH, Lim SD, et al. Clinical and pathological features and the BRAF(V600E) mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis. Thyroid 2009; 19: 137-41.
18. Lee HJ, Choi J, Hwang TS, Shong YK, Hong SJ, Gong G. Detection of BRAF mutations in thyroid nodules by allele-specific PCR using a dual priming oligonucleotide system. Am J Clin Pathol 2010; 133: 802-8.
19. Lyon E, Wittwer CT. LightCycler technology in molecular diagnostics. J Mol Diagn 2009; 11: 93-101.
20. Demers DB, Curry ET, Egholm M, Sozer AC. Enhanced PCR amplification of VNTR locus D1S80 using peptide nucleic acid (PNA). Nucleic Acids Res 1995; 23: 3050-5.
21. Jeong D, Jeong Y, Lee J, et al. Rapid and sensitive detection of KRAS mutation by peptide nucleic acid-based real-time PCR clamping: a comparison with direct sequencing between fresh tissue and formalin-fixed and paraffin embedded tissue of colorectal cancer. Korean J Pathol 2011; 45: 151-9.
22. Guan H, Ji M, Bao R, et al. Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. J Clin En docrinol Metab 2009; 94: 1612-7.
23. Kim JY, Moon SJ, Kim KR, Sohn CY, Oh JJ. Dietary iodine intake and urinary iodine excretion in normal Korean adults. Yonsei Med J 1998; 39: 355-62.
24. Kim JY, Kim KR. Dietary iodine intake and urinary iodine excretion in patients with thyroid diseases. Yonsei Med J 2000; 41: 22-8.
25. Ibrahem S, Seth R, O'Sullivan B, Fadhil W, Taniere P, Ilyas M. Comparative analysis of pyrosequencing and QMC-PCR in conjunction with high resolution melting for KRAS/BRAF mutation detection. Int J Exp Pathol 2010; 91: 500-5.
26. Kyger EM, Krevolin MD, Powell MJ. Detection of the hereditary hemochromatosis gene mutation by real-time fluorescence polymerase chain reaction and peptide nucleic acid clamping. Anal Biochem 1998; 260: 142-8.
27. Thiede C, Bayerdorffer E, Blasczyk R, Wittig B, Neubauer A. Simple and sensitive detection of mutations in the ras proto-oncogenes using PNA-mediated PCR clamping. Nucleic Acids Res 1996; 24: 983-4.
28. Lee JH, Lee ES, Kim YS. Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer 2007; 110: 38-46.
29. Ahmad T, Eisen T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res 2004; 10(18 Pt 2): 6388S-92S.
30. Sala E, Mologni L, Truffa S, Gaetano C, Bollag GE, Gambacorti-Passerini C. BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. Mol Cancer Res 2008; 6: 751-9.